Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Antimicrob Agents Chemother ; 54(5): 2206-8, 2010 May.
Article in English | MEDLINE | ID: mdl-20211890

ABSTRACT

Using 98 clinical methicillin-susceptible Staphylococcus aureus isolates of known beta-lactamase (Bla) type, we found a pronounced inoculum effect for cephalexin (mostly Bla type A and C strains), a mild inoculum effect for cephalothin (especially types B and C), and no inoculum effects for ceftriaxone and cefuroxime. Ceftobiprole showed the lowest MICs at a high inoculum but with a slight increase for Bla-positive versus Bla-negative strains. Since a potential therapeutic effect associated with a cephalosporin inoculum effect has been described, further studies are warranted.


Subject(s)
Anti-Bacterial Agents/pharmacology , Cephalosporins/pharmacology , Staphylococcal Infections/drug therapy , Staphylococcus aureus/drug effects , Staphylococcus aureus/growth & development , Ceftriaxone/pharmacology , Cefuroxime/pharmacology , Cephalexin/pharmacology , Cephalothin/pharmacology , Humans , Methicillin , Microbial Sensitivity Tests
2.
Antimicrob Agents Chemother ; 53(8): 3437-41, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19487449

ABSTRACT

Methicillin (meticillin)-susceptible Staphylococcus aureus (MSSA) strains producing large amounts of type A beta-lactamase (Bla) have been associated with cefazolin failures, but the frequency and impact of these strains have not been well studied. Here we examined 98 MSSA clinical isolates and found that 26% produced type A Bla, 15% type B, 46% type C, and none type D and that 13% lacked blaZ. The cefazolin MIC(90) was 2 microg/ml for a standard inoculum and 32 microg/ml for a high inoculum, with 19% of isolates displaying a pronounced inoculum effect (MICs of >or=16 microg/ml with 10(7) CFU/ml) (9 type A and 10 type C Bla producers). At the high inoculum, type A producers displayed higher cefazolin MICs than type B or C producers, while type B and C producers displayed higher cefamandole MICs. Among isolates from hemodialysis patients with MSSA bacteremia, three from the six patients who experienced cefazolin failure showed a cefazolin inoculum effect, while none from the six patients successfully treated with cefazolin showed an inoculum effect, suggesting an association between these strains and cefazolin failure (P = 0.09 by Fisher's exact test). In summary, 19% of MSSA clinical isolates showed a pronounced inoculum effect with cefazolin, a phenomenon that could explain the cases of cefazolin failure previously reported for hemodialysis patients with MSSA bacteremia. These results suggest that for serious MSSA infections, the presence of a significant inoculum effect with cefazolin could be associated with clinical failure in patients treated with this cephalosporin, particularly when it is used at low doses.


Subject(s)
Anti-Bacterial Agents/pharmacology , Cefazolin/pharmacology , Staphylococcus aureus/drug effects , Bacteremia/drug therapy , Cefamandole/pharmacology , Cefazolin/therapeutic use , Humans , Methicillin/pharmacology , Microbial Sensitivity Tests , Staphylococcal Infections/drug therapy , Treatment Failure , beta-Lactamases/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...